CBI Announces Partnership With Children's Rare Disease Network and The Global Genes Project

BOSTON, April 28, 2011 /PRNewswire/ -- The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce a partnership with the Children's Rare Disease Network and The Global Genes Project for the 6th Annual Rare Disease Leadership Summit coming up July 12 - 13, 2011 at the Doubletree Hotel in Washington, D.C.

There is nothing rare about rare diseases. They affect few people individually, but there are more than 25 million children and their families in the US alone that are affected and approximately 250 million people diagnosed with a rare disease worldwide. Throughout two days of government, advocacy and industry presentations, you will learn how to ensure access to orphan drug therapies through collaborative efforts with government, researchers and patient groups.  

The two-day event features presentations from Amicus Therapeutics, NIH, Viropharma Incorporated, BioGenerator, Pfizer Inc, FDA, Kakkis EveryLife Foundation, Genetic Alliance UK, Health Canada, Keck Graduate Institute, Mobius Therapeutics LCC, CORD, Shire, The Children's Rare Disease Network and more.

To further their efforts to support the advancement of research in the rare disease arena, the Global Genes Project continues their "Wear That You Care™" Denim Campaign during the Rare Disease Leadership Summit. The campaign is simple - all attendees can participate in supporting the rare disease movement by wearing a Denim Jeans Ribbon™ on the first day of the conference, and their favorite pair of jeans on the second day.

Join us this July for what promises to be a thought-provoking and educational opportunity.

For more information on this event, please visit http://www.cbinet.com/RareDisease or call 800-817-8601. If you would like to apply for a press pass, please contact Lauren Donoghue at [email protected] or 339-298-2262.  

Sponsors and Exhibitors include Centric Health Resources, Siren Interactive, CRN, Cryer Health, MME, Almac and Plexius. For more information on sponsorship opportunities, please email Alexa Moore: [email protected].

About CBI:

A subsidiary of Advanstar Communications, CBI Research, Inc. offers Pharmaceutical and Healthcare conferences that serve senior executives and government officials by providing a unique platform for highly focused content and ideal networking opportunities with senior policy- and decision-makers. CBI events provide you with concrete, real-life examples that you can begin to apply at your organization immediately for significant impact on costs and revenue. For more information, please visit http://www.cbinet.com.

About the Children's Rare Disease Network:

The Children's Rare Disease Network works to educate and connect families, caregivers and stakeholders impacted by rare disease worldwide. CRDN is an online community and collaborative portal that includes resources, disease information and an active blog, RARE Blog. For more information, please visit http://www.crdnetwork.org.

About The Global Genes Project:

The Global Genes Project was developed as a collaborative grassroots campaign to educate and drive greater public awareness about rare disease, build community and support the development of effective therapies and treatments for children within their lifetime. For more information, please visit http://www.globalgenesproject.org.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE CBI Research, Inc.

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.